BJDX Bluejay Diagnostics announces successful completion of enrollment in the symon-ii multicenter clinical validation study Bluejay Diagnos
BJDX Bluejay Diagnostics announces successful completion of enrollment in the symon-ii multicenter clinical validation study Bluejay Diagnostics - preliminary symon-ii data show 17% 28-day mortality rate
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.